Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21516

Shown on this page

Current sort

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia
Interventions: GO-203-2c, GO-203-2c + Decitabine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease
Interventions: Trontinemab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 24
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 20 more

Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions: Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 37
States / cities: Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more

Conditions: Asthma
Interventions: Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage; Biological
Lead sponsor: Benjamin Medoff; Other
Eligibility: 18 Years to 50 Years
Enrollment: 313 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy; Drug · Behavioral · Other
Lead sponsor: MGH Institute of Health Professions; Other
Eligibility: 25 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gout
Interventions: Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg, Colchicine 1.2 mg, Naproxen 500 Mg, Prednisone 40 mg; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more

Conditions: Alopecia Areata
Interventions: Ritlecitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 23 more

Conditions: Paroxysmal AF
Interventions: Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Jonesboro, Arkansas • La Jolla, California • Sacramento, California + 19 more

Conditions: Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 81
States / cities: Phoenix, Arizona • La Jolla, California • Madera, California + 60 more

Conditions: Stereotypical Prolonged Seizures
Interventions: Staccato alprazolam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 12 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 66
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more

Conditions: Schizophrenia, Autism-Related Irritability
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 58
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 48 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions: Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Clinical trials in Boston, Massachusetts

Filter and sort this location

Institutions in Boston

Live official records

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

The CARDIOPROTECT Trial